The U.S Food and Drug Administration (FDA) has granted approval to ImmunityBio, Inc. (NASDAQ: IBRX) for their immunotherapy treatment, ANKTIVA® (N-803), in combination with Bacillus Calmette-Guérin (BCG), for patients with BCG-unresponsive non-muscle invasive bladder...
The Lupus Research Alliance (LRA), during the first anniversary meeting of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), proudly announced an expanded partnership with the U.S. Food and Drug Administration (FDA). This new collaboration includes the...
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug...
After a hectic month, the FDA’s calendar appears to be easing up a bit. In the next two weeks, the regulator is facing just three major target action dates, including one potential CAR-T therapy approval that could push the class into earlier lines of treatment for...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LB-P8, LISCure Biosciences’ investigational drug for the treatment of primary sclerosing cholangitis (PSC), a rare, chronic, cholestatic liver disease with significant unmet...
